Monoclonal antibody G250 targeting CA Ⅸ: Binding specificity, internalization and therapeutic effects in a non‑renal cancer model

Zatovicova,Miriam; Jelenska,Lenka; Hulikova,Alzbeta; Ditte,Peter; Ditte,Zuzana; Csaderova,Lucia; Svastova,Eliska; Schmalix,Wolfgang; Boettger,Volker; Bevan,Paul; Pastorek,Jaromir; Pastorekova,Silvia

doi:10.3892/ijo.2014.2658

Monoclonal antibody G250 targeting CA Ⅸ: Binding specificity, internalization and therapeutic effects in a non‑renal cancer model

Authors:
- Miriam Zatovicova
- Lenka Jelenska
- Alzbeta Hulikova
- Peter Ditte
- Zuzana Ditte
- Lucia Csaderova
- Eliska Svastova
- Wolfgang Schmalix
- Volker Boettger
- Paul Bevan
- Jaromir Pastorek
- Silvia Pastorekova
View Affiliations

Affiliations: Department of Molecular Medicine, Institute of Virology, Slovak Academy of Sciences, 84505 Bratislava, Slovakia, WILEX AG, 81675 Munich, Germany
Published online on: September 17, 2014 https://doi.org/10.3892/ijo.2014.2658
Pages: 2455-2467

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

G250 (Girentuximab) is a chimeric IgG1 monoclonal antibody (MAb) currently being evaluated as an immunotherapy for kidney cancer. It targets carbonic anhydrase protein (CA Ⅸ), a transmembrane carbonic anhydrase (CA) isoform, which is regulated by VHL/HIF pathway and hence expressed in the majority of renal cell carcinomas (RCCs) as well as in hypoxic non‑RCC tumours. CA Ⅸ functions in pH regulation and cell migration/invasion, and supports tumour cell survival in hypoxia and/or acidosis. It contains a highly active extracellular catalytic domain (CA) extended N‑terminally with a proteoglycan‑like region and C‑terminally with short transmembrane and intracellular regions. Here we characterize the binding and internalization properties of G250, as well as its therapeutic effects in animal model, and discuss the impact of G250‑mediated immunotherapy in non‑RCC tumours. We demonstrated that G250 MAb recognizes a conformational epitope in the CA domain, detects the soluble CA Ⅸ ectodomain (ECD), but not the splicing variant, and does not cross‑react with CA Ⅰ, Ⅱ, and Ⅻ isoforms. We showed that G250 internalizes via clathrin‑coated vesicles, escapes degradation in lysosomes and enters the recycling pathway via the perinuclear compartment. This results in long intracellular persistence and enables consecutive internalization cycles. Moreover, the recycled antibody maintains an intact Fc portion potentially capable of continuous induction of antibody‑dependent cell‑mediated cytotoxicity (ADCC) response, thus explaining its therapeutic efficacy. Finally, we showed that G250 treatment is effective against HT‑29 colorectal carcinoma xenografts that differ from RCC by more heterogeneous, hypoxia‑related expression of CA Ⅸ. These results suggest potential therapeutic usefulness of the G250 MAb in non‑RCC tumours.

View Figures

View References

1	Pastorekova S, Parkkila S, Pastorek J and Supuran CT: Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J Enzyme Inhib Med Chem. 19:199–229. 2004.PubMed/NCBI
2	Pastoreková S, Parkkila S, Parkkila AK, Opavský R, Zelník V, Saarnio J and Pastorek J: Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. Gastroenterology. 112:398–408. 1997.PubMed/NCBI
3	Pastorekova S, Parkkila S and Zavada J: Tumor-associated carbonic anhydrases and their clinical significance. Adv Clin Chem. 42:167–216. 2006. View Article : Google Scholar : PubMed/NCBI
4	Mandriota SJ, Turner KJ, Davies DR, Murray PG, Morgan NV, Sowter HM, Wykoff CC, Maher ER, Harris AL, Ratcliffe PJ and Maxwell PH: HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell. 1:459–468. 2002. View Article : Google Scholar : PubMed/NCBI
5	Potter C and Harris AL: Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle. 3:164–167. 2004. View Article : Google Scholar : PubMed/NCBI
6	Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, Wilson GD, Turley H, Talks KL, Maxwell PH, et al: Hypoxia-inducible regulation of tumor-associated carbonic anhydrases. Cancer Res. 60:7075–7083. 2000.PubMed/NCBI
7	Svastová E, Hulíková A, Rafajová M, Zat’ovicová M, Gibadulinová A, Casini A, Cecchi A, Scozzafava A, Supuran CT, Pastorek J and Pastoreková S: Hypoxia activates the capacity of tumour-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett. 577:439–445. 2004.PubMed/NCBI
8	Ditte P, Dequiedt F, Svastova E, Hulikova A, Ohradanova-Repic A, Zatovicova M, Csaderova L, Kopacek J, Supuran CT, Pastorekova S and Pastorek J: Phosphorylation of carbonic anhydrase IX controls its ability to mediate extracellular acidification in hypoxic tumors. Cancer Res. 71:7558–7567. 2011. View Article : Google Scholar : PubMed/NCBI
9	Dorai T, Sawczuk IS, Pastorek J, Wiernik PH and Dutcher JP: The role of carbonic anhydrase IX overexpression in kidney cancer. Eur J Cancer. 41:2935–2947. 2005. View Article : Google Scholar : PubMed/NCBI
10	Chiche J, Ilc K, Laferrière J, Trottier E, Dayan F, Mazure NM, Brahimi-Horn MC and Pouysségur J: Hypoxia-inducible carbonic anhydrase IX and XII promote tumour cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res. 69:358–368. 2009. View Article : Google Scholar : PubMed/NCBI
11	Dubois L, Peeters S, Lieuwes NG, Geusens N, Thiry A, Wigfield S, Carta F, McIntyre A, Scozzafava A, Dogné JM, et al: Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumour irradiation. Radiother Oncol. 99:424–431. 2011. View Article : Google Scholar : PubMed/NCBI
12	McIntyre A, Patiar S, Wigfield S, Li JL, Ledaki I, Turley H, Leek R, Snell C, Gatter K, Sly WS, et al: Carbonic anhydrase IX promotes tumour growth and necrosis in vivo and inhibition enhances anti-VEGF therapy. Clin Cancer Res. 18:3100–3111. 2012. View Article : Google Scholar : PubMed/NCBI
13	Svastová E, Zilka N, Zat’ovicová M, Gibadulinová A, Ciampor F, Pastorek J and Pastoreková S: Carbonic anhydrase reduces E-cadherin-mediated adhesion of MDCK cells via interaction with beta-catenin. Exp Cell Res. 290:332–345. 2003.PubMed/NCBI
14	Svastova E, Witarski W, Csaderova L, Kosik I, Skvarkova L, Hulikova A, Zatovicova M, Barathova M, Kopacek J, Pastorek J and Pastorekova S: Carbonic anhydrase IX interacts with bicarbonate transporters in lamellipodia and increases cell migration via its catalytic domain. J Biol Chem. 287:3392–3402. 2012. View Article : Google Scholar : PubMed/NCBI
15	Csaderova L, Debreova M, Radvak P, Stano M, Vrestiakova M, Kopacek J, Pastorekova S and Svastova E: The effect of carbonic anhydrase IX on focal contacts during cell spreading and migration. Front Physiol. 4:2712013. View Article : Google Scholar : PubMed/NCBI
16	Závada J, Závadová Z, Pastoreková S, Ciampor F, Pastorek J and Zelník V: Expression of MaTu-MN protein in human tumor cultures and in clinical specimens. Int J Cancer. 54:268–274. 1993.PubMed/NCBI
17	Zatovicova M, Jelenska L, Hulikova A, Csaderova L, Ditte Z, Ditte P, Goliasova T, Pastorek J and Pastorekova S: Carbonic anhydrase IX as an anticancer therapy target: preclinical evaluation of internalizing monoclonal antibody directed to catalytic domain. Curr Pharm Des. 16:3255–3263. 2010. View Article : Google Scholar : PubMed/NCBI
18	Lou Y, McDonald PC, Oloumi A, Chia S, Ostlund C, Ahmadi A, Kyle A, Auf dem Keller U, Leung S, Huntsman D, et al: Targeting tumor hypoxia: suppression of breast tumour growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res. 71:3364–3376. 2011. View Article : Google Scholar : PubMed/NCBI
19	Rafajová M, Zatovicová M, Kettmann R, Pastorek J and Pastoreková S: Induction by hypoxia combined with low glucose or low bicarbonate and high posttranslational stability upon reoxygenation contribute to carbonic anhydrase IX expression in cancer cells. Int J Oncol. 24:995–1004. 2004.PubMed/NCBI
20	Zatovicova M, Sedlakova O, Svastova E, Ohradanova A, Ciampor F, Arribas J, Pastorek J and Pastorekova S: Ectodomain shedding of the hypoxia-induced carbonic anhydrase IX is a metalloprotease-dependent process regulated by TACE/ADAM17. Br J Cancer. 93:1267–1276. 2005. View Article : Google Scholar : PubMed/NCBI
21	Zatovičová M and Pastorekova S: Modulation of cell surface density of carbonic anhydrase IX by shedding of the ectodomain and endocytosis. Acta Virol. 57:257–264. 2013.PubMed/NCBI
22	Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, Pauwels EK, Jonas U, Zwartendijk J and Warnaar SO: Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer. 38:489–494. 1986. View Article : Google Scholar : PubMed/NCBI
23	Oosterwijk-Wakka JC, Boerman OC, Mulders PF and Oosterwijk E: Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma. Int J Mol Sci. 14:11402–11423. 2013. View Article : Google Scholar : PubMed/NCBI
24	Zat’ovicová M, Tarábková K, Svastová E, Gibadulinová A, Mucha V, Jakubícková L, Biesová Z, Rafajová M, Ortova Gut M, Parkkila S, et al: Monoclonal antibodies generated in carbonic anhydrase IX-deficient mice recognize different domains of tumour-associated hypoxia-induced carbonic anhydrase IX. J Immunol Methods. 282:117–134. 2003.
25	Pastorek J and Pastorekova S: Molecular mechanisms regulating expression and function of cancer-associated anhydrase IX. The Tumour Microenvironment. Bagley RG: Springer New York: Humana Press, NY; pp. 59–90. 2010, View Article : Google Scholar
26	Xu C, Lo A, Yammanuru A, Tallarico AS, Brady K, Murakami A, Barteneva N, Zhu Q and Marasco WA: Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology. PLoS One. 5:e96252010. View Article : Google Scholar
27	Murri-Plesko MT, Hulikova A, Oosterwijk E, Scott AM, Zortea A, Harris AL, Ritter G, Old L, Bauer S, Swietach P and Renner C: Antibody inhibiting enzymatic activity of tumour-associated carbonic anhydrase isoform IX. Eur J Pharmacol. 657:173–183. 2011. View Article : Google Scholar : PubMed/NCBI
28	Supuran CT: Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov. 7:168–181. 2008. View Article : Google Scholar : PubMed/NCBI
29	Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, Latif F, Liu S, Chen F, Duh FM, et al: Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet. 7:85–90. 1994. View Article : Google Scholar : PubMed/NCBI
30	Ivanov SV, Kuzmin I, Wei MH, Pack S, Geil L, Johnson BE, Stanbridge EJ and Lerman MI: Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc Natl Acad Sci USA. 95:12596–12601. 1998. View Article : Google Scholar : PubMed/NCBI
31	Wiesener MS, Münchenhagen PM, Berger I, Morgan NV, Roigas J, Schwiertz A, Jürgensen JS, Gruber G, Maxwell PH, Löning SA, et al: Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res. 61:5215–5222. 2001.PubMed/NCBI
32	Raval RR, Lau KW, Tran MGB, Sowter HM, Mandriota SJ, Li JL, Pugh CW, Maxwell PH, Harris AL and Ratcliffe PJ: Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol. 25:5675–5686. 2005. View Article : Google Scholar : PubMed/NCBI
33	Bui MH, Seligson D, Han KR, Pantuck AJ, Dorey FJ, Huang Y, Horvath S, Leibovich BC, Chopra S, Liao SY, et al: Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 9:802–811. 2003.PubMed/NCBI
34	Brouwers AH, Frielink C, Oosterwijk E, Oyen WJ, Corstens FH and Boerman OC: Interferons can upregulate the expression of the tumor associated antigen G250-MN/CA IX, a potential target for (radio)immunotherapy of renal cell carcinoma. Cancer Biother Radiopharm. 18:539–547. 2003. View Article : Google Scholar : PubMed/NCBI
35	Atkins M, Regan M, McDermott D, Mier J, Stanbridge E, Youmans A, Febbo P, Upton M, Lechpammer M and Signoretti S: Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res. 11:3714–3721. 2005. View Article : Google Scholar : PubMed/NCBI
36	Chrastina A, Závada J, Parkkila S, Kaluz S, Kaluzová M, Rajcáni J, Pastorek J and Pastoreková S: Biodistribution and pharmacokinetics of 125I-labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma. Int J Cancer. 105:873–881. 2003. View Article : Google Scholar
37	Pastorek J, Pastoreková S, Callebaut I, Mornon JP, Zelník V, Opavský R, Zat’ovicová M, Liao S, Portetelle D, Stanbridge EJ, et al: Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene. 9:2877–2888. 1994.
38	Grabmaier K, Vissers JL, De Weijert MC, Oosterwijk-Wakka JC, Van Bokhoven A, Brakenhoff RH, Noessner E, Mulders PA, Merkx G, Figdor CG, et al: Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int J Cancer. 85:865–870. 2000. View Article : Google Scholar : PubMed/NCBI
39	Oosterwijk E, Bander NH, Divgi CR, Welt S, Wakka JC, Finn RD, Carswell EA, Larson SM, Warnaar SO, Fleuren GJ, et al: Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J Clin Oncol. 11:738–750. 1993.PubMed/NCBI
40	Steffens MG, Boerman OC, Oosterwijk-Wakka JC, Oosterhof GO, Witjes JA, Koenders EB, Oyen WJ, Buijs WC, Debruyne FM, Corstens FH and Oosterwijk E: Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol. 15:1529–1537. 1997.PubMed/NCBI
41	Bleumer I, Knuth A, Oosterwijk E, Hofmann R, Varga Z, Lamers C, Kruit W, Melchior S, Mala C, Ullrich S, et al: A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer. 90:985–990. 2004. View Article : Google Scholar : PubMed/NCBI
42	Bleumer I, Oosterwijk E, Oosterwijk-Wakka JC, Völler MC, Melchior S, Warnaar SO, Mala C, Beck J and Mulders PF: A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma. J Urol. 175:57–62. 2006. View Article : Google Scholar
43	Siebels M, Rohrmann K, Oberneder R, Stahler M, Haseke N, Beck J, Hofmann R, Kindler M, Kloepfer P and Stief C: A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX^®) and interferon-alpha-2a in metastatic renal cell carcinoma patients. World J Urol. 29:121–126. 2011. View Article : Google Scholar : PubMed/NCBI
44	Belldegrun AS, Chamie K, Kloepfer P, Fall B, Bevan P, Störkel S, Wilhelm O and Pantuck AJ: ARISER: a randomized double blind phase III study to evaluate adjuvant cG250 treatment versus placebo in patients with high-risk ccRCC - results and implications for adjuvant clinical trials. J Clin Oncol. 31(Suppl; abs. 4507)2013.
45	Takacova M, Barathova M, Hulikova A, Ohradanova A, Kopacek J, Parkkila S, Pastorek J, Pastorekova S and Zatovicova M: Hypoxia-inducible expression of the mouse carbonic anhydrase IX demonstrated by new monoclonal antibodies. Int J Oncol. 31:1103–1110. 2007.PubMed/NCBI
46	Barathova M, Takacova M, Holotnakova T, Gibadulinova A, Ohradanova A, Zatovicova M, Hulikova A, Kopacek J, Parkkila S, Supuran CT, et al: Alternative splicing variant of the hypoxia marker carbonic anhydrase IX expressed independently of hypoxia and tumour phenotype. Br J Cancer. 98:129–136. 2008. View Article : Google Scholar : PubMed/NCBI
47	Závada J, Závadová Z, Zat’ovicová M, Hyrsl L and Kawaciuk I: Soluble form of carbonic anhydrase IX (CA IX) in the serum and urine of renal carcinoma patients. Br J Cancer. 89:1067–1071. 2003.
48	Hyrsl L, Zavada J, Zavadova Z, Kawaciuk I, Vesely S and Skapa P: Soluble form of carbonic anhydrase IX (CA IX) in transitional cell carcinoma of urinary tract. Neoplasma. 56:298–302. 2009. View Article : Google Scholar : PubMed/NCBI
49	Zhou GX, Ireland J, Rayman P, Finke J and Zhou M: Quantification of carbonic anhydrase IX expression in serum and tissue of renal cell carcinoma patients using enzyme-linked immunosorbent assay: prognostic and diagnostic potentials. Urology. 75:257–261. 2010. View Article : Google Scholar
50	Kock L, Mahner S, Choschzick M, Eulenburg C, Milde-Langosch K, Schwarz J, Jaenicke F, Müller V and Woelber L: Serum carbonic anhydrase IX and its prognostic relevance in vulvar cancer. Int J Gynecol Cancer. 21:141–148. 2011. View Article : Google Scholar : PubMed/NCBI
51	Müller V, Riethdorf S, Rack B, Janni W, Fasching PA, Solomayer E, Aktas B, Kasimir-Bauer S, Zeitz J, Pantel K, et al: Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer. Breast Cancer Res. 13:R712011.
52	Gigante M, Li G, Ferlay C, Perol D, Blanc E, Paul S, Zhao A, Tostain J, Escudier B, Negrier S and Genin C: Prognostic value of serum CA9 in patients with metastatic clear cell renal cell carcinoma under targeted therapy. Anticancer Res. 32:5447–5451. 2012.PubMed/NCBI
53	Takacova M, Bartosova M, Skvarkova L, Zatovicova M, Vidlickova I, Csaderova L, Barathova M, Breza J Jr, Bujdak P, Pastorek J, et al: Carbonic anhydrase IX is a clinically significant tissue and serum biomarker associated with renal cell carcinoma. Oncol Lett. 5:191–197. 2013.PubMed/NCBI
54	Alterio V, Hilvo M, Di Fiore A, Supuran CT, Pan P, Parkkila S, Scaloni A, Pastorek J, Pastorekova S, Pedone C, et al: Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX. Proc Natl Acad Sci USA. 106:16233–16238. 2009. View Article : Google Scholar : PubMed/NCBI
55	Dubois L, Lieuwes NG, Maresca A, Thiry A, Supuran CT, Scozzafava A, Wouters BG and Lambin P: Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model. Radiother Oncol. 92:423–428. 2009. View Article : Google Scholar : PubMed/NCBI
56	Dürrbach A, Angevin E, Poncet P, Rouleau M, Chavanel G, Chapel A, Thierry D, Gorter A, Hirsch R, Charpentier B, et al: Antibody-mediated endocytosis of G250 tumor-associated antigen allows targeted gene transfer to human renal cell carcinoma in vitro. Cancer Gene Ther. 6:564–571. 1999.PubMed/NCBI
57	Grantab R, Sivananthan S and Tannock IF: The penetration of anticancer drugs through tumour tissue as a function of cellular adhesion and packing density of tumour cells. Cancer Res. 66:1033–1039. 2006. View Article : Google Scholar
58	Sorkin A and von Zastrow M: Endocytosis and signalling: intertwining molecular networks. Nat Rev Mol Cell Biol. 10:609–622. 2009. View Article : Google Scholar : PubMed/NCBI
59	Surfus JE, Hank JA, Oosterwijk E, Welt S, Lindstrom MJ, Albertini MR, Schiller JH and Sondel PM: Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors. J Immunother Emphasis Tumor Immunol. 19:184–191. 1996. View Article : Google Scholar : PubMed/NCBI
60	Liu Z, Smyth FE, Renner C, Lee FT, Oosterwijk E and Scott AM: Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity. Cancer Immunol Immunother. 51:171–177. 2002. View Article : Google Scholar : PubMed/NCBI
61	Divgi CR, Pandit-Taskar N, Jungbluth AA, Reuter VE, Gönen M, Ruan S, Pierre C, Nagel A, Pryma DA, Humm J, et al: Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (¹²⁴I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol. 8:304–310. 2007. View Article : Google Scholar : PubMed/NCBI
62	Beasley NJ, Wykoff CC, Watson PH, Leek R, Turley H, Gatter K, Pastorek J, Cox GJ, Ratcliffe P and Harris AL: Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis and microvessel density. Cancer Res. 61:5262–5267. 2001.PubMed/NCBI
63	Turner KJ, Crew JP, Wykoff CC, Watson PH, Poulsom R, Pastorek J, Ratcliffe PJ, Cranston D and Harris AL: The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer. Br J Cancer. 86:1276–1282. 2002. View Article : Google Scholar : PubMed/NCBI
64	Swinson DE, Jones JL, Cox G, Richardson D, Harris AL and O’Byrne KJ: Hypoxia-inducible factor-1 alpha in non small cell lung cancer: relation to growth factor, protease and apoptosis pathways. Int J Cancer. 111:43–50. 2004. View Article : Google Scholar : PubMed/NCBI
65	Harris AL: Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer. 2:38–47. 2002. View Article : Google Scholar : PubMed/NCBI
66	Olive PL, Aquino-Parsons C, MacPhail SH, Laio S, Raleigh JA, Lerman MI and Stanbridge EJ: Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. Cancer Res. 61:8924–8929. 2001.PubMed/NCBI
67	Thiery JP and Sleeman JP: Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 7:131–142. 2006. View Article : Google Scholar : PubMed/NCBI